A Phase IIa Multicenter Double Blind Study to Evaluate the Efficacy and Safety of Low Doses of Oral NT-KO-003 for the Treatment of Multiple Sclerosis. [A Phase IIa Multicenter Double Blind Study to Evaluate the Efficacy and Safety of low doses of oral Diazoxide for the treatment of Multiple Sclerosis.]

Trial Profile

A Phase IIa Multicenter Double Blind Study to Evaluate the Efficacy and Safety of Low Doses of Oral NT-KO-003 for the Treatment of Multiple Sclerosis. [A Phase IIa Multicenter Double Blind Study to Evaluate the Efficacy and Safety of low doses of oral Diazoxide for the treatment of Multiple Sclerosis.]

Completed
Phase of Trial: Phase II

Latest Information Update: 14 May 2014

At a glance

  • Drugs Diazoxide (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions; Biomarker; Pharmacogenomic; Therapeutic Use
  • Acronyms NeuroAdvan
  • Sponsors Neurotec Pharma
  • Most Recent Events

    • 17 Mar 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 05 Jul 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 27 Mar 2013 Planned End Date changed from 1 Jun 2013 to 1 Sep 2013, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top